Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for etyqa tablets, 0.5mg/0.1mg and 1mg/0.5mg. Aurobindo Pharma’s etyqa tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Activella Tablets manufactured by Amneal Pharmaceuticals.
Etyqa tablets, are indicated as a treatment of moderate to severe vasomotor symptoms due to menopause, treatment of moderate to severe symptoms of vulvar, and vaginal atrophy due to menopause prevention of postmenopausal osteoporosis.
Etyqa tablets, has an estimated market size of US $34.5 million for the twelve months ending April 2023, as per IQVIA.
